Walleye Capital LLC Incyte Corp Put Options Transaction History

Walleye Capital LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$57.33 - $68.61 $91,728 - $109,776	-1,600 Reduced 35.56%	2,900 $191,000
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $813,762 - $1.01 Million	-15,900 Reduced 77.94%	4,500 $272,000
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $282,750 - $332,950	5,000 Added 32.47%	20,400 $1.16 Million
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $803,264 - $988,526	15,400 New	15,400 $966,000
Q2 2023 Aug 14, 2023	SELL	$60.95 - $75.51 $231,610 - $286,938	-3,800 Reduced 97.44%	100 $6,000
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $273,897 - $335,439	3,900 New	3,900 $281,000
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $1.21 Million - $1.64 Million	-19,100 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$73.04 - $95.72 $1.73 Million - $2.27 Million	-23,700 Reduced 55.37%	19,100 $1.67 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $2.24 Million - $2.66 Million	30,800 Added 256.67%	42,800 $3.18 Million
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $1.17 Million - $1.41 Million	-15,900 Reduced 56.99%	12,000 $1.02 Million
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $1.77 Million - $2.46 Million	27,900 New	27,900 $2.4 Million

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.